Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02412267 | Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)(DLBL) | completed | Phase 2 | 17 | National Cancer Centre, SingaporeOTHER | 1 | Mar 23, 2016 | clinicaltrials |
| NCT00322985 | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 |
| clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01457144 | Study of Mantle Cell Lymphoma Treatment by RiBVD(RIBVD) | completed | Phase 2 | 76 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01567475 | The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas((RAD001-R)) | completed | Phase 1 | 21 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT02296398 | Long-term Use of Romidepsin in Patients With CTCL | completed | — | 47 | Northwestern UniversityOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00618969 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | completed | Phase 2 | 2 | University of ArizonaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT01523860 | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma(FLE09) | completed | Phase 2 | 76 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01530594 | Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 440 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02316613 | Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) | completed | — | 260 | Hoffmann-La RocheINDUSTRY | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01205503 | Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release | completed | Phase 2 | 32 | Mara ChambersOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | completed | Phase 2 | 34 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02072967 | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | completed | — | 97 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00023530 | Blood and Marrow Transplant Clinical Research Network | completed | N/A | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00336843 | Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 19 | Asan Medical CenterOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01296256 | Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).(BeEAM2010-01) | completed | Phase 2 | 60 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00646750 | Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom(Z-BEAM LDGGB) | completed | Phase 2 | 31 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00597519 | A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT00240578 | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab | completed | — | 88 | GlaxoSmithKlineINDUSTRY | 0 | Feb 1, 2016 | clinicaltrials |
| NCT00648037 | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT | completed | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00179660 | Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 50 | Celgene CorporationINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01419691 | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00280878 | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma | completed | Phase 2 | 12 | Bayside HealthOTHER_GOV | 1 | Jan 15, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01459653 | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor(Monitor-GCSF) | completed | — | 1,496 | SandozINDUSTRY | 12 | Jan 11, 2016 | clinicaltrials |
| NCT00163748 | Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma | completed | Phase 2 | 40 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00163761 | Efficacy Study of Outpatient Therapy for Lymphoma | completed | Phase 2 | 90 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00354926 | Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma | completed | Phase 1 | 67 | Applied Molecular EvolutionINDUSTRY | 1 | Jan 7, 2016 | clinicaltrials |
| NCT00639054 | The Molecular Characterization of Multiple Myeloma at Relapse(MM-FISH/DNA) | completed | — | 134 | Rigshospitalet, DenmarkOTHER | 1 | Jan 7, 2016 | clinicaltrials |
| NCT01314014 | Imexon for Relapsed Follicular and Aggressive Lymphomas(ULYM11011) | completed | Phase 2 | 22 | University of RochesterOTHER | 1 | Jan 6, 2016 | clinicaltrials |
| NCT01820546 | Cancer Stem Cells in Multiple Myeloma | completed | — | 96 | Ankara UniversityOTHER | 1 | Jan 6, 2016 | clinicaltrials |
| NCT00141297 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | completed | Phase 1 | 74 | PfizerINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00453102 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | completed | Phase 2 | 18 | University of MiamiOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00588328 | The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00534820 | Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | N/A | 450 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Dec 17, 2015 | clinicaltrials |
| NCT00534989 | Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT | completed | N/A | 10 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00606216 | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy | completed | — | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Mar 23, 2016source: clinicaltrials